Jaguar Health

Historical price data

Jaguar Health is a commercial-stage biopharma company with a mission to bring sustainable, plant-based prescription medicines to market for urgent gastrointestinal needs. Its core achievement is the FDA-approved product Mytesi® (crofelemer) for HIV/AIDS-associated diarrhea, a first-in-class anti-secretory agent. The company's strategy leverages this approved asset to pursue multiple high-value follow-on indications, including cancer therapy-related diarrhea and rare diseases, while expanding into animal health and exploring new botanical entities through strategic ventures. Jaguar operates through a family of companies designed to maximize global development and commercial opportunities.

A platform centered on crofelemer, a first-in-class anti-secretory agent sustainably derived from the Croton lechleri tree, with a unique local mechanism of action inhibiting CFTR and CaCC chloride channels to treat diarrhea without causing constipation.